Organovo Holdings, Inc. — Form 10-Q Summary
Filing identity: The provided filing is for Organovo Holdings, Inc. (NYSE MKT: ONVO), not Vivosim Labs, Inc. It covers the quarter ended June 30, 2015—Organovo’s first quarter of fiscal 2016, rather than calendar 2015 Q1. The filing was signed August 10, 2015.
Business context
Organovo is an early commercial-stage company developing and commercializing 3D human tissues for drug testing, biological research, and potential therapeutic applications. Its first commercial product, exVive3D Human Liver Tissue, was released in November 2014. The company said it had not yet generated significant revenue from its planned principal operations.
Financial results and liquidity
| Metric | Three months ended June 30, 2015 | Comparable 2014 period |
|---|---|---|
| Total revenue | $306,000 | $99,000 |
| Operating expenses | $8.8 million | $6.5 million |
| Operating loss | $8.458 million | $6.410 million |
| Net loss | $8.491 million | $6.433 million |
| Net loss per share, basic and diluted | $0.10 | $0.08 |
| Net cash used in operations | $6.295 million | $3.365 million |
- Revenue increased about 209%. Current-quarter revenue included $209,000 from product and services, $14,000 from collaborations, and $83,000 from grants. Product and service revenue was zero in the comparable period.
- Operating expenses rose about 35%: research and development increased 50% to $4.142 million, while selling, general, and administrative expense increased 24% to $4.622 million. The filing does not provide gross profit or a gross margin.
- Cash and cash equivalents were $86.0 million at June 30, 2015, up from $50.142 million at March 31, 2015. Working capital was $81.8 million. The company reported total liabilities of $5.244 million, including a $2,000 capital lease obligation; no material borrowing balance is reported.
- Investing activities used $1.135 million, primarily for fixed-asset purchases. Financing activities provided $43.288 million, mainly from a June public offering. The offering raised approximately $43.2 million net and issued 10,838,750 shares, including the over-allotment.
- Shares outstanding increased from 81,536,724 at March 31 to 92,426,404 at June 30, 2015. Accumulated deficit was $130.8 million.
Changes, outlook, and risks
- Management attributed higher spending to expanded staffing, research and development, commercialization efforts, public-company costs, and facility expansion. R&D staff increased from 36 to 54 and administrative staff from 14 to 32 year over year.
- Management said cash on hand and expected receipts would fund operations, as then planned, for at least the next 12 months. It provided no quantified revenue, earnings, or cash-flow guidance.
- A $1.0 million customer upfront fee received during the quarter remained deferred because no deliverables had been completed. Total deferred revenue was approximately $1.452 million.
- Management cautioned that additional capital may be needed; future financing availability and terms are uncertain. Further equity issuance could dilute shareholders, while debt could impose payment and covenant restrictions. The company also highlighted risks around product development, market acceptance, and achieving sufficient revenue and profitability.
- Operating lease commitments totaled $6.847 million, including $1.151 million due in less than one year. The company disclosed an ongoing dispute with Spencer Trask Ventures over fees and confidentiality claims; the arbitration date had been removed from the calendar and could be rescheduled. No loss accrual was recorded, and management said the claims were without merit.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. It reported no material change to the risk factors from its prior annual report.
Important facts for investors to verify
- Confirm the issuer and reporting period: the filing is Organovo’s June 30, 2015 quarter, not a Vivosim Labs filing.
- Review whether commercial product and research-service demand grew enough to support the business, given low revenue and rising operating costs.
- Track quarterly cash burn, capital spending, and the company’s stated 12-month liquidity outlook.
- Assess dilution from the public offering, outstanding options and warrants, and any future equity or debt financing.
- Monitor the Spencer Trask arbitration, lease commitments, and the timing of recognition of deferred customer and collaboration revenue.